

Fig. 2. Histological evaluation of atherosclerotic areas of thoracic aortas from seven groups of rabbits. (Upper Left) Surface involvement of atherosclerotic areas in thoracic aorta. (Upper Center) Area occupied by atherosclerotic lesions of the aortic arch and thoracic aorta, Gp1. (Upper Right) The intima/media (I/M) ratio of the aortic arch and thoracic aorta. In each of the above, data are illustrated as the mean \pm SEM from six rabbits per group, and * signifies significant difference ($P < 0.05$) vs. Gp1. (Lower) Representative elastica van-Gieson (EVG)-staining photographic images of cross sections of thoracic aortas from seven groups of rabbits. Original magnification. The scale bar in the lower right corner of each image signifies 200 μ m.

Detection of eNOS, ets-Like Gene-1 (Elk-1), and Phosphorylated cAMP Response Element-Binding Protein (p-CREB). Tissue sections (5 mm) from arterial segments were homogenized (46), and Western blot analysis was performed (47). Gels were transblotted onto nitrocellulose membranes and blocked with milk powder overnight, and samples were incubated with monoclonal antibodies

(1:500 dilution for 1.5 h at room temperature) against Elk-1, p-CREB, and eNOS (epitope of NOS-III, no crossreactivity with NOS-I or -II; Santa Cruz Biotechnology) (46–48). Proteins were detected by chemiluminescence (Amersham Pharmacia Biotech enhanced chemiluminescence kit). All other details have been described (46–48).




Fig. 3. NO and superoxide production in thoracic aortas from seven groups of rabbits. (Left) Quantification of eNOS protein in thoracic aorta using Western blotting. The Western blot represents a single typical experiment. The bar graph illustrates data from six experiments. Relative amounts of eNOS protein are shown. (Right) Superoxide production in thoracic aortas of seven groups of rabbits ($n = 6$ per group). Kcpm, multiply numbers shown by 1,000. Data are illustrated as the mean \pm SEM from six rabbits per group. *, Significant difference ($P < 0.05$) vs. Gp1.

PHARMACOLOGY

Data Analysis. Results were expressed as mean \pm SEM and represent unpaired data. Data were compared by analysis of variance with repeated measurements. When a significant *F* value was obtained, Scheffé's test for multiple comparisons was used to identify the differences among groups. *P* values of <0.05 were considered to be statistically significant.

Results

Influence of Various Treatments on Blood Chemistry. All rabbits appeared to be healthy throughout the study. No significant differences in body weight or plasma triglycerides were observed among groups. Treatment with L-arginine plus L-citrulline with (Gp7-Mix) or without (Gp4-Arg+Cit) antioxidants showed a significant increase in plasma NO_x and cGMP levels, as compared with those of the HCD group (Gp1-HCD). However, antioxidant or L-arginine treatment alone had no such effect. Therefore, the combination of L-arginine and L-citrulline possesses the capacity to elevate both NO and cGMP. Presumably, cGMP is elevated because the increased NO production results in activation of soluble guanylate cyclase (Table 1).

Influence of Fatty Diet and NO-Boosting Supplements on Endothelium-Dependent Vasorelaxation in Thoracic Aorta and Tissue Blood Flow.

Acetylcholine elicited endothelium-dependent relaxation of aortic rings (Fig. 1), and the magnitude of relaxation in hypercholesterolemic animals (Gp1-HCD) was markedly diminished when compared with that of the regular diet group (Gp8-C). However, endothelium-dependent relaxation of the aorta from Gp7-Mix animals was remarkably greater than that from Gp1-HCD and was similar to that for Gp8-C animals. Aortic relaxation in Gp4-Arg+Cit, Gp2-Arg, Gp3-Cit, and Gp6-Arg+Vit tended to increase compared with that of the Gp1-HCD group. The endothelium-independent vasorelaxant, nitroglycerin, produced equivalent magnitudes of relaxation in all groups (data not shown). Indomethacin did not appreciably affect endothelium-dependent relaxation (data not shown). Blood flow near the right central ear artery showed a significant improvement in the Gp4-Arg+Cit and Gp7-Mix groups compared with Gp1-HCD (Fig. 1), and these findings are in agreement with the *in vitro* data from isolated aortic rings. Therefore, ingestion of NO-boosting supplements can improve endothelium-dependent relaxation in atherosclerotic rabbits.

Influence of Fatty Diet and NO-Boosting Supplements on Atheromatous Lesions in Thoracic Aorta.

Histological examination of the thoracic aorta revealed markedly smaller atheromatous lesions in the L-arginine plus L-citrulline treatment groups (Gp4-Arg-Cit and Gp7-Mix) than in the hypercholesterolemic group (Gp1) (Fig. 2). The atherosclerotic area was reduced by $>50\%$ in animals that received L-arginine, L-citrulline, and antioxidants. Note that the effective treatments also reduced the surface involvement of atherosclerosis and intima/media ratios (Fig. 2). Thus, the initial stages of atherosclerosis and plaque formation were both inhibited by treatment with L-arginine, L-citrulline, and antioxidants.

Influence of Fatty Diet and NO-Boosting Supplements on Protein Expression of eNOS in Thoracic Aorta.

Treatment of rabbits with L-citrulline alone (Gp3) and with the combination of L-arginine and L-citrulline (Gp4) and the combination of L-arginine, L-citrulline, and antioxidants (Gp7) caused a significant increase in eNOS protein expression as compared with Gp1 (Fig. 3). Interestingly, L-citrulline was more effective than L-arginine, and antioxidants tended to increase the effect of L-arginine (Gp6). These data indicate that NO-boosting supplements can up-regulate eNOS gene expression.




Fig. 4. Quantification of Elk-1 and p-CREB protein in thoracic aortas from seven groups of rabbits using Western blotting. Western blots represent a single typical experiment. The bar graphs illustrate data from six experiments. Data are illustrated as the mean \pm SEM from six rabbits per group. *, Significant difference ($P < 0.05$) vs. Gp1.

Inhibitory Action of NO-Boosting Supplements on the Increased Production of Superoxide Anion and Elk-1 and p-CREB Protein Expression in Aorta from Hypercholesterolemic Rabbits. O₂⁻ production was ≈ 3 -fold greater in aorta from hypercholesterolemic (Gp1-HCD) rabbits than from control (Gp8-C) rabbits (data not shown). Ingestion of L-arginine and/or L-citrulline tended to decrease O₂⁻ production, although the differences were not statistically significant (Fig. 3). However, the combination of antioxidants with L-arginine (Gp6-Arg+Vit) or L-arginine plus L-citrulline (Gp7-Mix) produced a marked reduction in O₂⁻ production (Fig. 3). In accord with the well known association between hypercholesterolemia and oxidative stress in tissues, a cholesterol-rich diet caused an increase in oxidation-sensitive Elk-1 and p-CREB expression (compare Gp1 and Gp8; Fig. 4). L-arginine plus L-citrulline, with (Gp7) or without (Gp4) antioxidants completely prevented cholesterol diet-induced increase in Elk-1 and p-CREB expression (Fig. 4). The combination of L-arginine plus antioxidants (Gp6) produced the same effect on p-CREB.

Discussion

The objective of the present study was to evaluate the influence of ingested L-arginine, L-citrulline, and antioxidants (vitamins C and E) on the progression of atherosclerosis in rabbits fed a HCD. The hallmark of diet-induced atherosclerosis in rabbits is vascular endothelial cell dysfunction, which is characterized by

marked impairment of endothelium-dependent vasorelaxation in isolated arteries as well as blood flow *in vivo* and atherosclerosis with distinct atheromatous lesions (3, 6, 30, 40, 45). Moreover, atherosclerosis is characterized by the progressive development of oxidative stress, as evidenced by the increased production of $O_2^{\cdot-}$ in arteries and increased expression of oxidation-sensitive genes such as Elk-1 and *p*-CREB (12, 13, 15, 25). The systemic administration of L-arginine and antioxidants to atherosclerotic animals has been demonstrated to slow the progression of disease (7, 12, 20–26). However, the effects of L-citrulline alone or in combination with L-arginine or L-arginine plus antioxidants have not been reported.

L-arginine plus L-citrulline, alone or with antioxidants, caused a marked improvement in endothelium-dependent vasorelaxation and rabbit ear blood flow, dramatic regression in atheromatous lesions, and decrease in $O_2^{\cdot-}$ production. These therapeutic effects were associated with concomitant increases in aortic eNOS expression and plasma levels of nitrite plus nitrate (NO_x) and cGMP. The data reveal that chronic ingestion of the dietary supplements used in this study promotes an increase in NO production and action. NO_x are stable oxidation products of NO and represent markers of NO production. cGMP is the intracellular second messenger that mediates many physiological actions of NO, and its formation is stimulated by NO. In view of the evidence that NO improves endothelial dysfunction, causes vasorelaxation *in vitro* and vasodilation *in vivo*, and slows the progression of atherosclerosis (1, 7, 8), it is reasonable to conclude that the pharmacological effects observed in rabbits after dietary supplementation with L-arginine, L-citrulline, and antioxidants are attributed to increased production and action of NO.

The chronic oral administration of L-arginine with or without antioxidants to mice was shown to increase the protein expression of eNOS in the aorta (25, 26). Similarly, in the present study, NO-boosting supplements caused a marked up-regulation of eNOS in rabbit aorta. In addition, L-citrulline was tested and found to increase eNOS protein expression. The combined administration of L-citrulline plus L-arginine, with or without antioxidants produced an even greater up-regulation of eNOS. eNOS up-regulation was accompanied by elevated plasma NO_x and cGMP, thereby indicating indirectly that the up-regulated eNOS was functionally active. There are at least two possible mechanisms by which L-arginine could have increased NO production. One is up-regulation of eNOS, and a second is increased availability of substrate (L-arginine) to eNOS. The latter mechanism might appear to be less likely than the first, because K_m for L-arginine as a substrate for eNOS is 2–15 μM , whereas plasma L-arginine levels in mammals are 100–200 μM , thereby suggesting that eNOS may already be saturated with substrate. This enigma has been termed the “arginine paradox.” However, current evidence suggests that the bulk of intracellular endothelial L-arginine may not be available for NO production. Plasmalemmal caveolae may be the principal source of L-arginine available to eNOS (18, 19). Moreover, the L-citrulline to L-arginine recycling pathway is localized to caveolae and may be the principal source of available L-arginine (17–19). Cytosolic L-arginine availability for eNOS may be limited by uptake into plasmalemmal caveolae (49), and administration of excess L-arginine may create a sufficient concentration gradient to make more L-arginine available to eNOS. Alternatively, the “arginine paradox” has been explained by the presence during atherosclerosis

of elevated levels of asymmetric dimethylarginine (ADMA), a competitive inhibitor of eNOS (5, 33–36, 50). Excess L-arginine could effectively compete with ADMA for binding sites on eNOS. Our observations both here and previously in mice (25, 26) that L-arginine can up-regulate eNOS offers a previously undescribed explanation of the “arginine paradox.”

L-citrulline, the second product of the NOS reaction, was reported to elicit endothelium-dependent relaxation of rat aorta accompanied by increases in tissue nitrite and cGMP (51). This is consistent with the knowledge that L-citrulline is converted to L-arginine by mammalian cells, including endothelial cells (16–19, 52, 53). This recycling pathway might be important in sustaining the production of NO in endothelial cells, especially when L-arginine becomes limiting, as is possible in atherosclerosis. In the present study, L-citrulline produced pharmacological effects that closely resembled those of L-arginine administration and NO action. L-citrulline caused a marked improvement in endothelium-dependent vasorelaxation in response to acetylcholine, and the combination of L-citrulline and L-arginine produced a synergistic response in elevating plasma NO_x and cGMP, improving rabbit ear artery blood flow and slowing the progression of atherosclerosis. A key observation was the marked up-regulation of eNOS on chronic administration of L-citrulline, and this response might explain, in part or entirely, the NO-like pharmacological effects of L-citrulline.

Atherosclerosis is an inflammatory disease characterized by endothelial dysfunction and impairment of NO production (1, 2, 8). Herein lies a plausible explanation for atherogenesis, because it is well appreciated that NO elicits a multifaceted array of pharmacological actions, all of which are protective against the progression of atherosclerosis (7, 8). A common feature of inflammation and atherosclerosis is oxidative stress (15), which can lead not only to cell membrane injury but also the destruction of NO. Thus, the natural antioxidant properties of NO are lost, and oxidative stress continues unabated. In the present study, fatty diet-induced atherosclerosis and oxidative stress were reversed upon oral administration of L-arginine, L-citrulline, and antioxidants. These observations suggest that NO is the active species in reducing both the markers for oxidative stress and the progression of atherosclerosis.

Cardiovascular disease is the leading cause of morbidity and untimely death both in men and women in the U.S. and may be largely avoidable and even reversible by adopting more sensible programs involving a healthy diet and moderate exercise. A diet low in saturated fat and rich in antioxidants could counter the development of oxidative stress and boost NO production and action (11, 13, 15, 31, 33). Likewise, moderate exercise would boost NO production and decrease the expression of oxidation-sensitive genes (26). The present study demonstrates, at least in rabbits, that chronic ingestion of L-arginine, L-citrulline, and antioxidants can reverse the progression of atherosclerosis. Similar observations were made in humans with L-arginine and antioxidants (5, 8, 27–29). Therefore, taken together, embarking on a low-fat and high-antioxidant-diet moderate exercise program and regimen of NO-boosting dietary supplements might result in a lower incidence of deaths attributed to cardiovascular disease.

This work was supported by a grant-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan, and the Japan Society for Promotion of Science [Grant in Aid for Science Research No. 16406001 (to T.H.), Awards for Eminent Scientists 2002–2004 (to L.J.I.), and Postdoctoral Fellowship for Foreign Researchers (to P.A.R.J.)].

1. Ross, R. (1999) *N. Engl. J. Med.* **340**, 115–126.
2. Cooke, J. P. (1998) *J. Invest. Med.* **46**, 377–380.
3. Hayashi, T., Ishikawa, T., Naito, M., Kuzuya, M., Funaki, C., Asai, K. & Kuzuya, F. (1991) *Atherosclerosis* **87**, 23–38.
4. Kauser, K., da Cunha, V., Fitch, R., Mallari, C. & Rubanyi, G. M. (2000) *Am. J. Physiol.* **278**, H1679–H1685.

5. Boger, R. H. & Bode-Boger, S. M. (2001) *Annu. Rev. Pharmacol. Toxicol.* **41**, 79–99.
6. Hayashi, T., Sumi, D., Juliet, P. A., Matsui-Hirai, H., Asai-Tanaka, Y., Kano, H., Fukatsu, A., Tsunekawa, T., Miyazaki, A., Iguchi, A., *et al.* (2004) *Cardiovasc. Res.* **61**, 339–351.
7. Ignarro, L. J. & Napoli, C. (2004) *Curr. Atherosclerosis Rep.* **6**, 281–287.

8. Cooke, J. P. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 768–770.
9. Ignarro, L. J., Cirino, G., Casini, A. & Napoli, C. (1999) *J. Cardiovasc. Pharmacol.* **34**, 879–886.
10. Ignarro, L. J., Buga, G. M., Wei, L.-H., Bauer, P. M., Wu, G. & del Soldato, P. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 4202–4208.
11. Diaz, M. N., Frei, B., Vita, J. A. & Keaney, J. F., Jr. (1997) *N. Engl. J. Med.* **337**, 408–416.
12. Boger, R. H., Bode-Boger, S. M., Mugge, A., Kienke, S., Brandes, R., Dwenger, A. & Frolich, J. C. (1995) *Atherosclerosis* **117**, 273–284.
13. Boger, R. H., Bode-Boger, S. M., Phivthong-ngam, L., Brandes, R. P., Schwedhelm, E., Mugge, A., Bohme, M., Tsikas, D. & Frolich, J. C. (1998) *Atherosclerosis* **141**, 31–43.
14. Napoli, C., Ackah, E., de Nigris, F., del Soldato, P., D'Armiento, F. P., Crimi, E., Condorelli, M. & Sessa, W. C. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 12467–12470.
15. de Nigris, F., Lerman, A., Ignarro, L. J., Williams-Ignarro, S., Sica, V., Baker, A. H., Lerman, L. O., Geng, Y. J. & Napoli, C. (2003) *Trends Mol. Med.* **9**, 351–359.
16. Hecker, M., Sessa, W. C., Harris, H. J., Anggard, E. E. & Vane, J. R. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 8612–8616.
17. Goodwin, B. L., Solomonson, L. P. & Eichler, D. C. (2004) *J. Biol. Chem.* **279**, 18353–18360.
18. Flam, B. R., Hartmann, P. J., Harrell-Booth, M., Solomonson, L. P. & Eichler, D. C. (2001) *Nitric Oxide* **5**, 187–197.
19. Solomonson, L. P., Flam, B. R., Pendleton, L. C., Goodwin, B. L. & Eichler, D. C. (2003) *J. Exp. Biol.* **206**, 2083–2087.
20. McNamara, D. B., Bedi, B., Aurora, H., Tena, L., Ignarro, L. J., Kadowitz, P. J. & Akers, D. L. (1993) *Biochem. Biophys. Res. Commun.* **193**, 291–296.
21. Cooke, J. P., Singer, A. H., Tsao, P., Zera, P., Rowan, R. A. & Billingham, M. E. (1992) *J. Clin. Invest.* **90**, 1168–1172.
22. Wang, B.-Y., Singer, A. H., Tsao, P. S., Drexler, H., Kosek, J. & Cooke, J. P. (1994) *J. Am. Coll. Cardiol.* **23**, 452–458.
23. Boger, R. H., Bode-Boger, S. M., Brandes, R. P., Phivthong-ngam, L., Bohme, M., Nafe, R., Mugge, A. & Frolich, J. C. (1997) *Circulation* **96**, 1282–1290.
24. Boger, R. H., Bode-Boger, S. M., Kienke, S., Stan, A. C., Nafe, R. & Frolich, J. C. (1998) *Atherosclerosis* **136**, 67–77.
25. de Nigris, F., Lerman, L. O., Williams-Ignarro, S., Sica, G., Lerman, A., Palinski, W., Ignarro, L. J. & Napoli, C. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 1420–1425.
26. Napoli, C., Williams-Ignarro, S., de Nigris, F., Lerman, L. O., Rossi, L., Guarino, C., Mansueto, G., Di Tuoro, F., Pignatola, O., De Rosa, G., et al. (2004) *Proc. Natl. Acad. Sci. USA* **101**, 8797–8802.
27. Drexler, H., Zeiher, A. M., Meinzer, K. & Hanjorg, J. (1991) *Lancet* **338**, 1546–1550.
28. Bode-Boger, S. M., Boger, R. H., Alfke, H., Heinzl, D., Tsikas, D., Creutzig, A., Alexander, K. & Frolich, J. C. (1996) *Circulation* **93**, 85–90.
29. Boger, R. H., Bode-Boger, S. M., Thiele, W., Creutzig, A., Alexander, K. & Frolich, J. C. (1998) *J. Am. Coll. Cardiol.* **32**, 1336–1344.
30. Hayashi, T., Sumi, D., Matsui-Hirai, H., Fukatsu, A., Arockia, Rani P. J., Kano, H., Tsunekawa, T. & Iguchi, A. (2003) *Atherosclerosis* **168**, 23–31.
31. Kleinveld, H. A., Demacker, P. N. M. & Stalenhoef, A. F. H. (1994) *Arterioscler. Thromb.* **14**, 1386–1391.
32. Esterbauer, H., Dieber-Rotheneder, M., Striegl, G. & Waeg, G. (1991) *Am. J. Clin. Nutr.* **53**, 314S–321S.
33. Sydow, K., Schwedhelm, E., Arakawa, N., Bose-Boger, S. M., Tsikas, D., Hornig, B., Frolich, J. C. & Boger, R. H. (2003) *Cardiovasc. Res.* **57**, 244–252.
34. Bode-Boger, S. M., Boger, R. H., Kienke, S., Junker, W. & Frolich, J. C. (1996) *Biochem. Biophys. Res. Commun.* **219**, 598–603.
35. Boger, R. H. & Bode-Boger, S. M. (2000) *Semin. Thromb. Hemostasis* **26**, 539–545.
36. Boger, R. H., Bode-Boger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F. & Cooke, J. P. (1998) *Circulation* **98**, 1842–1847.
37. Waugh, W. H., Doeschner, C. W., Files, B. A., McConnell, M. E. & Strandjord, S. E. (2001) *J. Natl. Med. Assoc.* **93**, 363–371.
38. Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W. & Fu, P. C. (1974) *Clin. Chem.* **20**, 470–475.
39. Department of Health, Education, and Welfare (1982) in *Lipid Research Clinics Program Manual of Laboratory Operations* (U.S. Govt. Printing Office), Vol. 1, Ed. 2, pp. 76–628.
40. Hayashi, T., Esaki, T., Muto, E., Kano, H., Asai, Y., Thakur, N.K., Sumi, D., Jayachandran, M. & Iguchi, A. (2000) *Arterioscler. Thromb. Vasc. Biol.* **20**, 782–792.
41. Okano, K., Takahashi, S., Yasuda, K., Tokinaga, D., Imai, K. & Koga, M. (1992) *Anal. Biochem.* **202**, 120–125.
42. Wardell, K., Jakobsson, A. & Nilsson, G. E. (1993) *IEEE Trans. Biomed. Eng.* **40**, 309–316.
43. Caballero, A. E., Arora, S., Saouaf, R., Lim, S. C., Smakowski, P., Park, J. Y., King, G. L., LoGerfo, F. W., Horton, E. S. & Veves, A. (1999) *Diabetes* **48**, 1856–1862.
44. Weiner, B. H., Ockene, I. S., Levine, P. H., Cuenoud, H. F., Fisher, M., Johnson, B. F., Daoud, A. S., Jarmolych, J., Hosmer, D. & Johnson, M. H. (1986) *N. Engl. J. Med.* **315**, 841–846.
45. Thakur, N. K., Hayashi, T., Sumi, D., Kano, H., Tsunekawa, T. & Iguchi, A. (2001) *Am. J. Physiol.* **281**, H75–H83.
46. Napoli, C., de Nigris, F., Welch, J. S., Calara, F. B., Stuart, R. O., Glass, C. K. & Palinski, W. (2002) *Circulation* **105**, 1360–1367.
47. de Nigris, F., Franconi, F., Maida, I., Palumbo, G., Anania, V. & Napoli, C. (2000) *Biochem. Pharmacol.* **59**, 1477–1487.
48. Jeremy, R. W., McCarron, H. & Sullivan, D. (1996) *Circulation* **94**, 498–506.
49. Hardy, T. A. & May, J. M. (2002) *Free Radic. Biol. Med.* **32**, 122–131.
50. Tsikas, D., Boger, R. H., Sandmann, J., Bode-Boger, S. M. & Frolich, J. C. (2000) *FEBS Lett.* **478**, 1–3.
51. Santhanam, A. V. & Dikshit, M. (2001) *Eur. J. Pharmacol.* **431**, 61–69.
52. Shuttleworth, C. W. R., Burns, A. J., Ward, S. M., O'Brien, W. E. & Sanders, K. M. (1995) *Neuroscience* **68**, 1295–1304.
53. Xie, L., Hattori, Y., Tume, N. & Gross, S. S. (2000) *Semin. Perinatol.* **24**, 42–45.